ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...
Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback